

Recommendation

The TFEC recommends the **non-inclusion** of **lapatinib** in the Philippine National Formulary (PNF) for the treatment of **HER2-positive breast cancer** due to lack of sufficient evidence to demonstrate superiority or non-inferiority compared to trastuzumab in terms of overall survival and risk of adverse events.:

- No statistical difference between lapatinib and trastuzumab in overall survival.
 - Ma et al. (2019): HR: 0.86, 95% CI (0.45 to 1.63)
 - Debiasi et al. (2019): HR range: 1.22 - 1.49, 95% Credible Interval: 0.72, 2.44
- Increased risk of adverse events
 - Diarrhea: RR range: 6.27 - 11.54; 95% CI (3.82 to 23.42)

References

The references cited in this summary document are lifted from the report by the Evidence Review Group unless otherwise specified.

Additional reference:

World Health Organization (2018). Pricing of cancer medicines and its impacts. Retrieved from <https://apps.who.int/iris/handle/10665/277190>